Could a light helmet boost Alzheimer's treatment?
NCT ID NCT06992804
First seen Sep 30, 2025 · Last updated Jun 22, 2026 · Updated 36 times
Summary
This early study tests whether adding daily near-infrared light therapy to the drug lecanemab can improve thinking and memory in people with mild Alzheimer's disease. Twenty participants will receive either real or sham light therapy plus lecanemab for 16 weeks, then all will get the real light therapy for up to 48 weeks. The goal is to see if the combination is safe and slows cognitive decline.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xuanwu Hospital, Capital Medical University
RECRUITINGBeijing, 100053, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
near-infrared light therapy combined with lecanemab (a drug)
What this could lead to
If it works, this could point toward a new combination treatment that slows cognitive decline in early Alzheimer's disease.
What could go wrong
This is a very early, small trial with only 20 people. The results may not be generalizable, and the combination may not show added benefit over lecanemab alone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.